Oncology Is More Complex. The Opportunity is to Make it Usable

ASCO 2026 made one thing clear: oncology innovation is advancing faster than the system's ability to absorb it - Omnicom Health @ ASCO 2026

Across pancreatic cancer, prostate cancer, lung cancer, breast cancer, and the growing AI conversation, the science became more powerful, but the decisions around it became harder. New data did not simply add options, it raised sharper questions about which patients to identify, which tests to run, which combinations to trust, which trade-offs to explain, and how to make increasingly sophisticated advances work in routine care.

Across tumor types, the most important story was not the arrival of more options alone, it was the rising complexity around how those options are selected, sequenced, explained, and put to work in real-world care. Oncology is earlier, more precise, more combinatorial, more platform-driven, and more operationally demanding.

The opportunity is not only to amplify positive results. It is to build the evidence narratives, education, tools, and brand stories that help clinicians understand which patients are most appropriate, when to act, how to weigh trade-offs, and what must happen across the care pathway for innovation to reach the people it is intended to help.

The marketing winners will be the teams that help clinicians translate data into decisions. Read more of our insights from ASCO 2026.